Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia

被引：5
|
作者：
Patel, Shyam A. [1 ,2 ]
机构：
[1] Stanford Univ, Dept Med, Div Hematol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Div Oncol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
来源：
JAMA ONCOLOGY | 2018年 / 4卷 / 08期
关键词：
MUTATIONS;
D O I：
10.1001/jamaoncol.2017.4724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1110 / +
页数：3
相关论文
共 50 条
  • [11] Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
    Dogra, Raghav
    Bhatia, Rohit
    Shankar, Ravi
    Bansal, Parveen
    Rawal, Ravindra K.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2018, 18 (14) : 1936 - 1951
  • [12] Clonal Heterogeneity in Differentiation Response and Resistance to the IDH2 Inhibitor Enasidenib in Acute Myeloid Leukemia
    Quek, Lynn
    David, Muriel
    Kennedy, Alison
    Metzner, Marlen
    Amatangelo, Michael
    Shih, Alan H.
    Stoilova, Bilyana
    Karamitros, Dimitris
    Quivoron, Cyril
    Heiblig, Mael
    Willekens, Christophe
    Saada, Veronique
    Peniket, Andrew
    Bernard, Olivier
    Agresta, Sam
    Yen, Katharine
    Stein, Eytan M.
    De Botton, Stephane
    Thakurta, Anjan
    Levine, Ross L.
    Penard-Lacronique, Virginie
    Vyas, Paresh
    BLOOD, 2017, 130
  • [13] Enasidenib, a targeted inhibitor of mutant IDH2 proteins for treatment of relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    FUTURE ONCOLOGY, 2018, 14 (01) : 23 - 40
  • [14] Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib
    Stein, Eytan M.
    DiNardo, Courtney D.
    Fathi, Amir T.
    Pollyea, Daniel A.
    Stone, Richard M.
    Altman, Jessica K.
    Roboz, Gail J.
    Patel, Manish R.
    Collins, Robert
    Flinn, Ian W.
    Sekeres, Mikkael A.
    Stein, Anthony S.
    Kantarjian, Hagop M.
    Levine, Ross L.
    Vyas, Paresh
    MacBeth, Kyle J.
    Tosolini, Alessandra
    VanOostendorp, Jason
    Xu, Qiang
    Gupta, Ira
    Lila, Thomas
    Risueno, Alberto
    Yen, Katharine E.
    Wu, Bin
    Attar, Eyal C.
    Tallman, Martin S.
    de Botton, Stephane
    BLOOD, 2019, 133 (07) : 676 - 687
  • [15] Enasidenib for Patients With Relapsed Acute Myeloid Leukemia and the IDH2 Mutation
    DiNardo, Courtney
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 247 - 249
  • [16] A Phase I Study of the IDH2 Inhibitor Enasidenib As Maintenance Therapy for IDH2-Mutant Myeloid Neoplasms Following Hematopoietic Cell Transplantation
    Fathi, Amir T.
    Li, Shuli
    Soiffer, Robert J.
    Levis, Mark
    Mims, Alice S.
    Devine, Steven M.
    Defilipp, Zachariah
    El-Jawahri, Areej
    McAfee, Steven L.
    Spitzer, Thomas R.
    Frigault, Matthew J.
    Dey, Bimalangshu R.
    Amrein, Philip C.
    Hobbs, Gabriela S.
    Brunner, Andrew M.
    Hock, Hanno R.
    Narayan, Rupa
    Knight, Laura W.
    Kelley, Devon
    Bottoms, Aj S.
    Brown, Jami L.
    Del Rio, Candice J.
    Vanderklish, Julie E.
    Danielson, Colleen
    Saylor, Meredith L.
    Hunnewell, Chrisa L.
    Perry, Lindsey H.
    Wahl, Jonathan L.
    Breton, Elayne
    Ho, Vincent T.
    Chen, Yi-Bin
    BLOOD, 2020, 136
  • [17] Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).
    Dinardo, Courtney Denton
    Stein, Anthony Selwyn
    Stein, Eytan M.
    Fathi, Amir Tahmasb
    Schuh, Andre C.
    Fernandez, Pau Montesinos
    Odenike, Olatoyosi
    Kantarjian, Hagop M.
    Stone, Richard M.
    Collins, Robert
    Martinelli, Giovanni
    Arnan, Montserrat
    Wu, Bin
    Koralek, Daniel O.
    Van Oostendorp, Jason
    Gong, Jing
    MacBeth, Kyle J.
    Vyas, Paresh
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [18] Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
    Quek, Lynn
    David, Muriel D.
    Kennedy, Alison
    Metzner, Marlen
    Amatangelo, Michael
    Shih, Alan
    Stoilova, Bilyana
    Quivoron, Cyril
    Heiblig, Mael
    Willekens, Christophe
    Saada, Veronique
    Alsafadi, Samar
    Vijayabaskar, M. S.
    Peniket, Andy
    Bernard, Oliver A.
    Agresta, Sam
    Yen, Katharine
    MacBeth, Kyle
    Stein, Eytan
    Vassiliou, George S.
    Levine, Ross
    De Botton, Stephane
    Thakurte, Anjan
    Penard-Lacronique, Virginie
    Vyas, Paresh
    NATURE MEDICINE, 2018, 24 (08) : 1167 - +
  • [19] Enasidenib Causing Differentiation Syndrome and Pulmonary Complications in a Patient with Acute Myeloid Leukemia
    Abdullah, A.
    Tsai, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [20] Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
    Lynn Quek
    Muriel D. David
    Alison Kennedy
    Marlen Metzner
    Michael Amatangelo
    Alan Shih
    Bilyana Stoilova
    Cyril Quivoron
    Maël Heiblig
    Christophe Willekens
    Véronique Saada
    Samar Alsafadi
    M. S. Vijayabaskar
    Andy Peniket
    Oliver A. Bernard
    Sam Agresta
    Katharine Yen
    Kyle MacBeth
    Eytan Stein
    George S. Vassiliou
    Ross Levine
    Stephane De Botton
    Anjan Thakurta
    Virginie Penard-Lacronique
    Paresh Vyas
    Nature Medicine, 2018, 24 : 1167 - 1177
12345